Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease
This study is looking at whether an FDA-approved medicine called Ceftriaxone (Rocephin®), given in small doses over time, can help people aged 18 to 75 who have Post-Treatment Lyme Disease (PTLDS). PTLDS means you had Lyme disease but still have symptoms even after treatment. The main goals are to see if Ceftriaxone is safe and well-tolerated compared to a placebo (a look-alike substance with no medicine), and if it improves symptoms. You would come to the clinic about every 5-6 days for 6 weeks to receive an IV infusion of either Ceftriaxone or the placebo. The study is planning to enroll 44 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 44 participants.
- What's involved
- You would come to the clinic approximately every 5-6 days for 9 IV infusions over 6 weeks. You would also have follow-up visits one month after the last treatment, and at approximately 3 and 6 months from the study start.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for one year. Those who received Ceftriaxone will have a phone call follow-up at 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease
At a glance
Conditions
NCT06611111
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
SUNY Upstate Medical University, Upstate Global Health Institute
East Syracuse, New Yorkno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Kristopher Paolino, MD · PRINCIPAL_INVESTIGATOR · State University of New York - Upstate Medical University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of abnormal laboratory measurements30 days post last treatment
Total number of all abnormal labs
- Intensity of Abnormal Laboratory Measurements30 days post final treatment
Graded according clinical laboratory normals and FDA toxicity scale
- Duration of Abnormal Laboratory Measurements30 days post final treatment
Number of days of abnormal lab
- Occurrence of adverse events30 days post last treatment
Total number of adverse events
- Intensity adverse events30 days post final treatment
Graded according FDA toxicity scale
- Duration of adverse events30 days post final treatment
Number of days per adverse event
- Number of serious adverse events1 year post study start
Total number